局部巨噬细胞调节乳膏促进糖尿病足伤口愈合(ON101):一个病例系列。

IF 1.7 4区 医学 Q3 DERMATOLOGY
Kwan Lok Benjamin Ng, Yun-Nan Lin, Wei-Yu Chen, Yi-Chia Wu, Shu-Hung Huang, Su-Shin Lee, Rong-Fu Chen, Yur-Ren Kuo
{"title":"局部巨噬细胞调节乳膏促进糖尿病足伤口愈合(ON101):一个病例系列。","authors":"Kwan Lok Benjamin Ng, Yun-Nan Lin, Wei-Yu Chen, Yi-Chia Wu, Shu-Hung Huang, Su-Shin Lee, Rong-Fu Chen, Yur-Ren Kuo","doi":"10.12968/jowc.2023.0318","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>A number of treatments have been developed to treat hard-to-heal (chronic) diabetic foot ulcers (DFUs). This case series the use of ON101-a new topical macrophage regulatory cream for the treatment of DFUs, that helped achieve limb-salvage outcomes with an adequate safety profile.</p><p><strong>Method: </strong>Patients with hard-to-heal DFUs-primarily on the toes and plantar surfaces-were enrolled in the study. After infection control, wound debridement or angioplasty intervention, ON101, containing 1.25% extracts of <i>Plectranthus amboinicus</i> (0.25%) and <i>Centella asiatica</i> (1%), was applied topically to the wounds up to twice daily. The condition of the wounds, complications, healing progression and other details were documented.</p><p><strong>Results: </strong>In total, 10 patients, with a mean age of 59.2 years (range: 35-77 years), were included in the study following surgical debridement, sequestrectomy or revascularisation. Wound sizes ranged from 1-66 cm<sup>2</sup>. After receiving ON101 treatment for durations ranging from 14-264 days, most wounds healed without complications, except for one patient with osteomyelitis who did not fully recover. All patients expressed satisfaction with the outcomes and had no reported complications at the six-month follow-up.</p><p><strong>Conclusion: </strong>This case series demonstrated the real-world outcomes of ON101, which exhibited good healing efficacy in the treatment of DFUs, making it a promising strategy for the topical treatment of these ulcers.</p>","PeriodicalId":17590,"journal":{"name":"Journal of wound care","volume":"34 Sup8","pages":"lxxiv-lxxx"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Enhancing diabetic foot wound healing with topical macrophage-regulating cream (ON101): a case series.\",\"authors\":\"Kwan Lok Benjamin Ng, Yun-Nan Lin, Wei-Yu Chen, Yi-Chia Wu, Shu-Hung Huang, Su-Shin Lee, Rong-Fu Chen, Yur-Ren Kuo\",\"doi\":\"10.12968/jowc.2023.0318\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>A number of treatments have been developed to treat hard-to-heal (chronic) diabetic foot ulcers (DFUs). This case series the use of ON101-a new topical macrophage regulatory cream for the treatment of DFUs, that helped achieve limb-salvage outcomes with an adequate safety profile.</p><p><strong>Method: </strong>Patients with hard-to-heal DFUs-primarily on the toes and plantar surfaces-were enrolled in the study. After infection control, wound debridement or angioplasty intervention, ON101, containing 1.25% extracts of <i>Plectranthus amboinicus</i> (0.25%) and <i>Centella asiatica</i> (1%), was applied topically to the wounds up to twice daily. The condition of the wounds, complications, healing progression and other details were documented.</p><p><strong>Results: </strong>In total, 10 patients, with a mean age of 59.2 years (range: 35-77 years), were included in the study following surgical debridement, sequestrectomy or revascularisation. Wound sizes ranged from 1-66 cm<sup>2</sup>. After receiving ON101 treatment for durations ranging from 14-264 days, most wounds healed without complications, except for one patient with osteomyelitis who did not fully recover. All patients expressed satisfaction with the outcomes and had no reported complications at the six-month follow-up.</p><p><strong>Conclusion: </strong>This case series demonstrated the real-world outcomes of ON101, which exhibited good healing efficacy in the treatment of DFUs, making it a promising strategy for the topical treatment of these ulcers.</p>\",\"PeriodicalId\":17590,\"journal\":{\"name\":\"Journal of wound care\",\"volume\":\"34 Sup8\",\"pages\":\"lxxiv-lxxx\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of wound care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.12968/jowc.2023.0318\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of wound care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12968/jowc.2023.0318","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:已经开发了许多治疗难以愈合的(慢性)糖尿病足溃疡(DFUs)的方法。本病例系列使用on101 -一种新的局部巨噬细胞调节乳膏治疗DFUs,有助于获得具有足够安全性的肢体挽救结果。方法:患者难以愈合的dfs -主要是在脚趾和足底表面-纳入研究。在感染控制、创面清创或血管成形术干预后,将ON101涂抹于创面,ON101中含有1.25%的安博菌(0.25%)和积雪草(1%)提取物,每日最多2次。记录伤口情况、并发症、愈合进展及其他细节。结果:共纳入10例患者,平均年龄59.2岁(范围:35-77岁),接受手术清创、隔离切除术或血运重建术。伤口大小从1-66平方厘米不等。在接受ON101治疗14-264天后,大多数伤口愈合无并发症,除了一名骨髓炎患者未完全恢复。在6个月的随访中,所有患者都对结果表示满意,没有出现并发症。结论:本病例系列证明了ON101的实际疗效,在治疗DFUs中表现出良好的愈合效果,使其成为局部治疗这些溃疡的有希望的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Enhancing diabetic foot wound healing with topical macrophage-regulating cream (ON101): a case series.

Objective: A number of treatments have been developed to treat hard-to-heal (chronic) diabetic foot ulcers (DFUs). This case series the use of ON101-a new topical macrophage regulatory cream for the treatment of DFUs, that helped achieve limb-salvage outcomes with an adequate safety profile.

Method: Patients with hard-to-heal DFUs-primarily on the toes and plantar surfaces-were enrolled in the study. After infection control, wound debridement or angioplasty intervention, ON101, containing 1.25% extracts of Plectranthus amboinicus (0.25%) and Centella asiatica (1%), was applied topically to the wounds up to twice daily. The condition of the wounds, complications, healing progression and other details were documented.

Results: In total, 10 patients, with a mean age of 59.2 years (range: 35-77 years), were included in the study following surgical debridement, sequestrectomy or revascularisation. Wound sizes ranged from 1-66 cm2. After receiving ON101 treatment for durations ranging from 14-264 days, most wounds healed without complications, except for one patient with osteomyelitis who did not fully recover. All patients expressed satisfaction with the outcomes and had no reported complications at the six-month follow-up.

Conclusion: This case series demonstrated the real-world outcomes of ON101, which exhibited good healing efficacy in the treatment of DFUs, making it a promising strategy for the topical treatment of these ulcers.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of wound care
Journal of wound care DERMATOLOGY-
CiteScore
2.90
自引率
10.50%
发文量
215
期刊介绍: Journal of Wound Care (JWC) is the definitive wound-care journal and the leading source of up-to-date research and clinical information on everything related to tissue viability. The journal was first launched in 1992 and aimed at catering to the needs of the multidisciplinary team. Published monthly, the journal’s international audience includes nurses, doctors and researchers specialising in wound management and tissue viability, as well as generalists wishing to enhance their practice. In addition to cutting edge and state-of-the-art research and practice articles, JWC also covers topics related to wound-care management, education and novel therapies, as well as JWC cases supplements, a supplement dedicated solely to case reports and case series in wound care. All articles are rigorously peer-reviewed by a panel of international experts, comprised of clinicians, nurses and researchers. Specifically, JWC publishes: High quality evidence on all aspects of wound care, including leg ulcers, pressure ulcers, the diabetic foot, burns, surgical wounds, wound infection and more The latest developments and innovations in wound care through both preclinical and preliminary clinical trials of potential new treatments worldwide In-depth prospective studies of new treatment applications, as well as high-level research evidence on existing treatments Clinical case studies providing information on how to deal with complex wounds Comprehensive literature reviews on current concepts and practice, including cost-effectiveness Updates on the activities of wound care societies around the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信